Hypothesis I
1 To whom correspondence should be addressed Commencement of GnRH agonist, either as a single dose of This debate was previously published on Webtrack 96, the long-acting form or as daily s.c. doses, results in an initial December 1, 1999 transient 'flare-up effect' on the pituitary leading to a surge of circulating gonadotrophins. It is postulated that this surge Pituitary desensitization with gonadotrophin-releasing hortriggers the growth of the primordial follicles. The absence of mone (GnRH) agonists prior to ovarian stimulation is now a a subsequent luteinizing hormone (LH) surge prevents the routine part of most in-vitro fertilization (IVF) and intracytorupture or luteinization of the follicles which then get converted plasmic sperm injection (ICSI) procedures. The two criteria into cystic structures. This hypothesis was first proposed to which are used to determine whether pituitary desensitization explain the presence of ovarian cysts after GnRH agonist has occurred are: (i) serum oestradiol concentrations of Ͻ50 administration (Feldberg et al., 1989) and then later by most pg/ml and (ii) the absence of any ovarian cysts with a diameter other investigators reporting on the presence of ovarian cysts Ͼ15-20 mm (Ron-El et al., 1989; Sampaio et al., 1991; after administration of GnRH agonists ( Herman et al., 1990; Tarlatzis et al., 1994; Keltz et al., 1995) . It takes Ron-El et al., 1990; Stewart et al., 1992; Jenkins et al., 1993; 10-15 days for this effect of GnRH agonist to manifest on Tarlatzis et al., 1994) . the ovary, irrespective of the phase of the cycle (early follicular
The incidence of ovarian cyst formation following GnRH phase or mid-luteal phase) in which the GnRH agonist is agonist treatment in IVF cycles is related to the serum started, the type of GnRH agonist used (long-acting triptorelin progesterone concentrations on the day of GnRH agonist or short-acting buserelin or leuprolide acetate) and the mode treatment initiation (Marqalioth et al., 1991) and is lower when of administration (nasal spray, i.m. administration of longprogesterone is administered prior to starting GnRH agonist acting preparations or s.c. administration) (Sampaio et al. treatment (Aston et al., 1995) . This is attributed to the ability 1991; Parinaud et al., 1992; Jenkins et al., 1993) . of progesterone to decrease gonadotrophin release in response There have been several reports on the presence of ovarian to GnRH agonist (Araki et al., 1985) , therefore the initial cysts while the women are still undergoing treatment with transient 'flare-up effect' of GnRH agonist becomes subdued GnRH agonists (Feldberg et al., 1989; Ron-El et al., 1989;  and subsequently the formation of cysts. This hypothesis Sampaio et al., 1991; Jenkins et al., 1992; Parinaud et al., explains the presence or formation of ovarian cysts after GnRH 1992; Stewart et al., 1992; Jenkins et al., 1993; Tarlatzis et al., agonist administration, but fails to explain how these 'cysts' 1994; Keltz et al., 1995; Weissman et al., 1998) . The elevated continue growing and secreting oestradiol in the absence of concentrations of serum oestradiol and the high concentration any endogenous or exogenous gonadotrophin stimulation for of oestradiol in the fluids aspirated from these cysts indicate a prolonged period of time. that these cysts originate from the ovarian follicles and have Several authors (Ron-El et al., 1989; Herman et al., 1990 ) been termed as 'functional follicular cysts' (Jenkins et al., have clearly demonstrated that there is a sharp rise in the 1993). Some of these cysts may also be endometriomata serum FSH and LH concentrations within the first 48 h of (Yanushpolsky et al., 1998) .
GnRH agonist administration with a concomitant rise in The incidence of formation of such cysts is reported to be oestradiol concentrations. Daily administration of buserelin or 2-40% (Feldberg et al., 1989; Ron-El et al., 1989 ; Parinaud leuprolide acetate for 4 days after the administration of longet al., 1992; Jenkins et al., 1993; Tarlatzis et al., 1994) . There acting GnRH agonist results in a decrease in both serum are some reports that the incidence is higher in older women gonadotrophin and oestradiol values. In cases where these (Keltz et al., 1995) ; in those in whom GnRH agonists have cysts have been observed, the gonadotrophin concentrations been started in the follicular phase, compared with those in decrease but the diameter of the cysts and circulating oestradiol whom it is started in the mid-luteal phase (Ben-Rafael et al., concentrations are maintained or increase (Herman et al., 1990) . 1990); and in those having higher basal (day 2) values of According to this hypothesis, if it is the 'flare-up' effect of follicle stimulating hormone (FSH) in the pre-treatment cycle (Keltz et al., 1995) . The reasons for the formation of such the GnRH agonist which triggers the rise in gonadotrophin values in the first 48 h which results in primordial follicle definitive evidence of direct action of GnRH on the ovary. The second premise (on which this hypothesis is based) is development and oestradiol production; then, once the gonadotrophin concentrations drop in circulation, the oestradiol itself questionable. The granulosa cells obtained for this study were from gonadotrophin-stimulated women undergoing concentrations should also drop over the next few days. However, this does not occur. Oestradiol production by these follicular aspiration for IVF. These cells were therefore already primed with gonadotrophins. GnRH agonist-induced steroido-'cysts' continues. It may be possible that these cysts act as a reservoir for oestradiol and could be responsible for maingenesis by these cells is, therefore, not a clear indication of direct action by GnRH on the ovaries. taining serum oestradiol concentrations, despite a lack of FSH stimulation. However, this still does not explain why the There is one more report on 'direct action' of GnRH agonist on the monkey granulosa cells which has not been cited by diameter of these cysts continues to increase, suggesting that there is another mechanism which results in the formation and any of the previous publications reporting on the formation of cysts during GnRH agonist treatment: (i) the GnRH agonist growth of cysts during GnRH agonist administration.
Even in women who are at a risk of ovarian hyperstimulation exerted a direct dose-dependent stimulative effect on the aromatase activity and progesterone production in cultured syndrome (OHSS) because of extremely high concentrations of oestradiol in serum, after pituitary desensitization followed monkey granulosa cells; (ii) the stimulative effect on steroidogenesis can be completely blocked by concomitant treatment by ovarian stimulation, a period of 'coasting' where gonadotrophins are discontinued but GnRH agonists are continued, with a GnRH antagonist, suggesting that the actions of GnRH are mediated through stringent stereo-specific recognition sites; results in a drop in oestradiol concentrations after 48 h of coasting (Sher et al., 1995; Tortoriello et al., 1998) .
(iii) in addition to the stimulative effect, the GnRH agonist in the presence of gonadotrophins also exerts an inhibitory effect, There have even been reports on the occurrence of severe OHSS following the administration of GnRH agonists alone even though the peptide by itself is more effective in the stimulation of steroidogenesis, and the stimulation of gonad- (Weissman et al., 1998) . This hypothesis, which can explain the occurrence or formation of cysts following GnRH agonists, otrophin on steroidogenesis could be gradually restored by decreasing the concentration of the GnRH agonist in the culture thus fails to explain how these follicular cysts continue growing and the presence of high circulating concentrations of oestradiol (Liu et al., 1991) . We had also observed a case where a woman developed an after prolonged use of GnRH agonists. ovarian cyst 2.5 cm in diameter while on 500 µg GnRH Hypothesis II agonist (buserelin) s.c for 14 days. This 21 year old woman, undergoing IVF with embryo transfer, had a history of two Pituitary desensitization may take Ͼ15 days in some women. In some of the reports on the presence of 'functional ovarian ectopic pregnancies. One of the Fallopian tubes had been removed while the other was blocked. Pituitary desensitization cysts' and serum oestradiol values of Ͼ50 pg/ml, the authors have not reported on the concentration of FSH and LH in was achieved as indicated by the very low values of FSH and LH (Ͻ1.5 IU/ml) 14 days after starting GnRH agonist. Despite serum at that point in time (Sampaio et al., 1991; Jenkins et al., 1992; Stewart et al., 1992; Tarlatzis et al., 1994) . It is pituitary desensitization, the ovaries were active as indicated by the increase in the diameter of the follicular cyst (1-2.5 probable that the circulating gonadotrophin concentrations may not have dropped down to that of a 'hypophysectomized stage'. cm), the number of follicles (there was only one follicle, Ͼ0.5 cm, at the time of starting the GnRH agonist but after 14 days This also explains why in some women, continuation of GnRH agonist for a few more days prior to starting stimulation brings there were three more follicles with a diameter of 0.9 cm); serum oestradiol concentrations after 14 days were 146 pg/ml; about both a drop in the serum oestradiol concentrations and the size of the cysts (Sampaio et al., 1991; Parinaud et and the thickness of the endometrium increased from 0.5 mm on the day of starting GnRH agonist to 1.05 cm after 14 days. al., 1992).
However, this cannot be the only explanation for the Ovarian stimulation with human menopausal gonadotrophin (HMG) was commenced after 14 days of GnRH agonist and occurrence of ovarian cysts while women are on GnRH agonists because 'functional cysts' are reported, despite achievthe dose of GnRH agonist was decreased from 500 to 100 µg. The diameter of the cyst did not change. A total of 13 oocytes ing pituitary desensitization as evidenced by low concentrations of FSH and LH (Feldberg et al., 1989; Jenkins et al., 1994;  were aspirated and fertilized in vitro. Eight embryos developed and three 4-cell embryos were transferred on day 2 after IVF. Weissman et al., 1998) .
No pregnancy resulted.
Hypothesis III
Thus our observation is similar to the earlier reports. The cyst may have been formed as proposed in hypothesis one; as It has also been postulated that GnRH agonists may have a direct effect on the ovaries and steroidogenesis (Sampaio et the serum FSH and LH concentrations were first measured after 14 days of GnRH agonist, it remains unclear whether al Parinaud et al., 1992) . This hypothesis is primarily based on two premises: (i) reports on the presence of GnRH pituitary desensitization took longer in this woman. However, as the values of FSH and LH were very low, it is more likely receptors on the ovary (Latouche et al., 1989; Namiki et al., 1990) ; and (ii) reports of GnRH agonist-induced steroidogenthat this case along with earlier reports (Liu et al. 1991; Weissman et al., 1998) supports the hypothesis that GnRH esis by cultured human granulosa cells (Parinaud et al., 1992; Bussenot et al., 1993) .
agonists have a direct effect on the ovarian steroidogenesis which is independent of its action on the pituitary. More inThe detection of receptors for GnRH in the ovary is not Cyst formation in GnRH agonist-treated cycles to serum progesterone on the day of analogue treatment initiation. [Abstr. vivo and in-vitro studies need to be carried out to demonstrate No. 44.] Hum. Reprod., 6 (Suppl. 1), 15. a direct effect of GnRH agonists on the ovary. If GnRH Namiki, T. (1990) Autoradiographic study on the distribution of gonadotropinreceptors are found to be functionally active in the ovary, then releasing hormone receptor in the rat ovary. Nippon Sanka Fujinka Gakkai Zasshi, 42, 1175 Zasshi, 42, -1181 this must be considered when designing IVF stimulation Parinaud, J., Cohen, K., Oustry, P. et al. (1992) Influence of ovarian cysts on protocols using GnRH antagonists.
the results of in vitro fertilization. Fertil. Steril., 58, 1174 -1177 . Ron-El, R., Herman, A., Golan, A. et al. (1989 Herman, A., Golan, A. et al. (1990) The comparison of early Subsequent to the submission of this manuscript, the patient follicular and midluteal administration of long-acting gonadotropin-releasing whose case was reported here underwent another attempt at hormone agonist. Fertil. Steril., 54, [233] [234] [235] [236] [237] ovarian stimulation for IVF/embryo transfer. GnRHa (500 µg Sampaio, M., Serra, V., Miro, F. et al. (1991) Development of ovarian cysts during gonadotrophin-releasing hormone agonists (GnRHa) administration.
per day s.c) was started in the mid-luteal phase (Day 21) of Hum. Reprod., 6, [194] [195] [196] [197] the pretreatment cycle. 10 days after GnRH agonist treatment, Sher, G., Zouves, C., Feinman, M. and Maassarani, G. (1995) serum oestradiol concentrations had increased to 330 pg/ml Tarlatzis, B.C., Bili, H., Bontis, J. et al. (1994) Follicle cyst formation after while the serum FSH and LH levels were 1.2 mIU/ml and administration of different gonadotrophin-releasing hormone analogues for Ͻ1 mIU/ml respectively. assisted reproduction. Hum. Reprod., 9, 1983 Reprod., 9, -1986 The increase in the number and size of cysts, the rise in the GnRH agonist has direct effect on ovarian steroidogenesis hyperstimulation following the sole administration of agonistic analogues of gonadotrophin-releasing hormone. Hum. Reprod., 13, [3421] [3422] [3423] [3424] which is independent of its action on the pituitary.
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